GlassScriptPhysician profile
Jane N Miriti
NPI 1033752407
$1,203.31
in general payments reported to CMS, 2019-2025
18 companies · $16.30 in 2025
The $16.30 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $423 · 2023: $457 · 2024: $163 · 2025: $16.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.89 | 2021-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $161.31 | 2021-2023 | Emgality, Jardiance, Mounjaro |
| Gilead Sciences, INC. | $136.29 | 2022-2023 | Epclusa |
| Abbvie INC. | $101.50 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $71.77 | 2021-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $61.54 | 2023-2024 | Invega Sustenna |
| Sumitomo Pharma America, INC. | $53.09 | 2023-2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $51.25 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $48.10 | 2022-2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.98 | 2023-2024 | Jardiance |
| Pfizer INC. | $33.13 | 2024 | |
| Sunovion Pharmaceuticals INC. | $31.36 | 2022 | |
| Glaxosmithkline, LLC. | $17.40 | 2022 | |
| Sanofi Pasteur INC. | $16.58 | 2021 | |
| Novo Nordisk INC | $16.30 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.41 | 2021 | |
| Astellas Pharma US INC | $13.13 | 2022 | |
| Merck Sharp & Dohme LLC | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Miriti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.